Another characteristic of the drug that was improved in the presence of n-3 PUFAs is its ability to prevent hepatic fibrosis as measured through the TGFβ-dependent induction of the COL1A1 gene expression in HepG2 cells. This evidence concerns the gene COL1A1 and Hepatic fibrosis.